SCHEMBL5569151

SCHEMBL5569151

CNCCOc1cccc(NC(=O)Nc2cccc(Oc3ccnc(C(=O)NC)c3)c2)c1C(F)(F)F

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RET P07949 4/20 0.61
KDR P35968 4/20 0.59
ABL1 P00519 3/20 0.59
EPHA2 P29317 3/20 0.59
MAPK14 Q16539 3/20 0.59
MAP3K20 Q9NYL2 3/20 0.59
SRC P12931 3/20 0.59
PLK4 O00444 2/20 0.59
AURKA O14965 2/20 0.59
MAPK13 O15264 2/20 0.59
MAP4K4 O95819 2/20 0.59
LCK P06239 2/20 0.59
FYN P06241 2/20 0.59
LYN P07948 2/20 0.59
RPS6KB1 P23443 2/20 0.59
AXL P30530 2/20 0.59
FRK P42685 2/20 0.59
MAPK9 P45984 2/20 0.59
BLK P51451 2/20 0.59
CAMK2B Q13554 2/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5569782 0.94 KDR (0.63) RETKDRABL1EPHA2MAPK14
SCHEMBL5568262 0.92 RET (0.58) RETKDRABL1EPHA2MAPK14
SCHEMBL5568939 0.92 RET (0.61) RETKDRABL1EPHA2MAPK14
SCHEMBL5565143 0.90 RET (0.60) RETKDRABL1EPHA2MAPK14
SCHEMBL14453623 0.89 RAF1 (0.67) RETKDRABL1EPHA2MAPK14
SCHEMBL5570160 0.88 RET (0.66) RETKDRABL1EPHA2MAPK14
SCHEMBL5568248 0.88 RET (0.61) RETKDRABL1EPHA2MAPK14
SCHEMBL5569608 0.87 RET (0.57) RETKDRABL1EPHA2MAPK14
SCHEMBL14453625 0.86 GSK3B (0.71) RETKDRABL1EPHA2MAPK14
SCHEMBL5569067 0.86 RAF1 (0.60) RETKDRABL1EPHA2MAPK14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-2007519653-A 2007-07-19 JP claimed
US-20070161677-A1 Bisarylurea derivatives MERCK PATENT GMBH (DE) 2007-07-12 US claimed
EP-1730111-A2 SUBSTITUTED BISARYLUREA DERIVATIVES AS KINASE INHIBITORS MERCK PATENT GmbH (DE) 2006-12-13 EP claimed
WO-2005075425-A2 SUBSTITUTED BISARYLUREA DERIVATIVES AS KINASE INHIBITORS MERCK PATENT GMBH (DE) 2005-08-18 WO claimed
US-20070161677-A1 Bisarylurea derivatives MERCK PATENT GMBH (DE) 2007-07-12 US disclosed
EP-1730111-A2 SUBSTITUTED BISARYLUREA DERIVATIVES AS KINASE INHIBITORS MERCK PATENT GmbH (DE) 2006-12-13 EP disclosed
WO-2005075425-A2 SUBSTITUTED BISARYLUREA DERIVATIVES AS KINASE INHIBITORS MERCK PATENT GMBH (DE) 2005-08-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070161677-A1 Bisarylurea derivatives BRAF, RAF1, NRAS RET 40/4885KDR 532/4885ABL1 15/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.